↓ Skip to main content

Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies

Overview of attention for article published in Cancer Immunology Research, September 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
3 tweeters
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies
Published in
Cancer Immunology Research, September 2018
DOI 10.1158/2326-6066.cir-18-0102
Pubmed ID
Authors

Jing Chang, Haiyong Peng, Brian C. Shaffer, Sivasubramanian Baskar, Ina C. Wecken, Matthew G. Cyr, Gustavo J. Martinez, Jo Soden, Jim Freeth, Adrian Wiestner, Christoph Rader

Abstract

Although the five-year survival rate of chronic lymphocytic leukemia (CLL) patients has risen to >80%, the only potentially curative treatment is allogeneic hematopoietic stem cell transplantation (alloHSCT). To identify possible new monoclonal antibody (mAb) drugs and targets for CLL, we previously developed a phage display-based human mAb platform to mine the antibody repertoire of patients who responded to alloHSCT. We had selected a group of highly homologous post-alloHSCT mAbs that bound to an unknown CLL cell surface antigen. Here we show through next-generation sequencing of cDNAs encoding variable heavy-chain domains that these mAbs had a relative abundance of ~0.1% in the post-alloHSCT antibody repertoire and were enriched ~1,000-fold after three rounds of selection on primary CLL cells. Based on differential RNA-seq and a cell microarray screening technology for discovering human cell surface antigens, we now identify their antigen as Siglec-6. We verified this finding by flow cytometry, ELISA, siRNA knockdown, and surface plasmon resonance. Siglec-6 was broadly expressed in CLL and could be a potential target for antibody-based therapeutic interventions. Our study reaffirms the utility of post-alloHSCT antibody drug and target discovery.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 29%
Librarian 1 7%
Student > Ph. D. Student 1 7%
Other 1 7%
Professor > Associate Professor 1 7%
Other 1 7%
Unknown 5 36%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 21%
Immunology and Microbiology 3 21%
Agricultural and Biological Sciences 1 7%
Neuroscience 1 7%
Engineering 1 7%
Other 0 0%
Unknown 5 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2022.
All research outputs
#3,637,661
of 21,401,022 outputs
Outputs from Cancer Immunology Research
#363
of 1,324 outputs
Outputs of similar age
#69,801
of 296,672 outputs
Outputs of similar age from Cancer Immunology Research
#7
of 29 outputs
Altmetric has tracked 21,401,022 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,324 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,672 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.